Integrated pharmacokinetics and pharmacodynamics in drug development

Clinical Pharmacokinetics

Volumn 46, Issue 9, 2007, Pages 713-737

  Dingemanse, Jasper ^a   Appel Dingemanse, Silke ^b  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CAPECITABINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CORTICOSTEROID; DISUFENTON SODIUM; DIURETIC AGENT; DOCETAXEL; DOPAMINE TRANSPORTER; ENTACAPONE; ETANERCEPT; EXENDIN 4; FINGOLIMOD; INSULIN; INTERFERON; LEVODOPA; NEUROLEPTIC AGENT; OPIATE; PEMETREXED; PLACEBO; QUETIAPINE; RANITIDINE; TOLRESTAT;

ANALYTIC METHOD; CLINICAL TRIAL; COMPUTER SIMULATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG INDUSTRY; DRUG LABELING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; EMPIRICAL RESEARCH; HUMAN; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; PARKINSON DISEASE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VALIDITY;

CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 34548305252     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746090-00001     Document Type: Review

References (189)

1. Hrusovsky K. Getting on the critical path: better evaluation tools for drug discovery and development. Drug Discov Today 2006 Sep; 11 (17-18): 773-4
2. Schmid EF, Smith DA. R&D technology investments: misguided and expensive or a better way to discover medicines? Drug Discov Today 2006 Sep; 11 (17-18): 775-84
3. Schmid EF, Smith DA. Trends in pharmaceutical innovation. Ann Rep Med Chem 2005; 40: 451-9
4. Tufts Center for the Study of Drug Development (CSSD). Tufts Center for the Study of Drug Development pegs cost of a new prescription medicine at $802 million [online]. 2001 Nov. Available from URL: http://csdd.tufts. edu/NewsEvents/RecentNews.asp?.newsid=6 [Accessed 2007 Apr 26]
5. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002; 20 (3 Suppl.): 11-29
6. Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Res 2003; 9: 891-902
7. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004 Aug; 3 (8): 711-5
8. US FDA. Innovation or stagnation: challenge and opportunity on the critical path to new medical products [online]. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [Accessed 2007 Apr 26]
9. US FDA. Innovation or stagnation: critical path opportunities report [online]. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/ reports/opp_report.pdf [Accessed 2007 Apr 26]
10. US FDA. Innovation or stagnation: critical path opportunities list [online]. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/ reports/opp_list.pdf [Accessed 2007 Apr 26]
11. Breimer DD, Danhof M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development: the 'wooden shoe' paradigm. Clin Pharmacokinet 1997 Apr; 32 (4): 259-67
12. Derendorf H, Lesko LJ, Chaikin P, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 2000; 40: 1399-418
13. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95
14. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006 Jun; 33 (3): 227-79
15. Levy G. Predicting effective drug concentrations for individual patients: determinants of pharmacodynamic variability. Clin Pharmacokinet 1998 Apr; 34 (4): 323-33
16. Abdel-Rahman SM, Kauffman RE. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol 2004; 44: 111-36
17. Lin JH. Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab 2006 Jan; 7 (1): 39-65
18. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005 Sep; 78 (3): 260-77
19. Ieiri I, Takane H, Hirota T, et al. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol 2006 Oct; 2 (5): 651-74
20. Workman P, Aboagye EO, Chung YL, et al. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 2006; 98: 580-98
21. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005 Nov; 11 (22): 7967-85
22. Sun C, Huth JR, Hajduk PJ. NMR in pharmacokinetic and pharmacodynamic profiling. Chembiochem 2005; 6: 1592-600
23. Fischman AJ, Alpert NM, Babich JW, et al. The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 1997 Nov; 29 (4): 923-56
24. De Lange ECM, Ravenstijn PGM, Groenendaal D, et al. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism based pharmacokinetic-pharmacodynamic modeling. AAPS J 2005; 7 (3): E532-43
25. Bouw MR, Xie R, Tunblad K, et al. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats: pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 2001; 134: 1796-804
26. Morikawa N, Mori T, Kawashima H, et al. Pharmacokinetics of anticancer drugs in cerebrospinal fluid. Ann Pharmacother 1998 Oct; 32: 1008-12
27. Colburn WA. Selecting and validating biologic markers for drug development. J Clin Pharmacol 1997 May; 37: 355-62
28. Colburn WA. Optimizing the use of biomarkers, surrogate end-points, and clinical endpoints for more efficient drug development. J Clin Pharmacol 2000 Dec; 40: 1419-27
29. Colburn WA. Biomarkers in drug discovery and development: from target identification through drug marketing. J Clin Pharmacol 2003 Apr; 43: 329-41
30. Colburn WA, Lee JW. Biomarkers, validation and pharmacokinetic- pharmacodynamic modelling. Clin Pharmacokinet 2003; 42 (12): 997-1022
31. Woodcock J. US National Institutes of Health. Biomarkers: physiological & laboratory markers of drug effect [online]. Available from URL: http://clinicalcenter.nih.gov/researchers/training/principles/ppt/ Physiological_Laboratory_Markers_of_Drug_Effect_2005-2006.ppt#1 [Accessed 2007 Apr 26]
32. Lepist E-I, Jusko WJ. Modeling and allometric scaling of s (+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Therap 2004; 27: 211-8
33. Huntjens DRH, Danhof M, Della Pasqua OED. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology 2005; 44: 846-59
34. Danhof M, Alvan G, Dahl SG, et al. Mechanism-based pharmacokinetic- pharmacodynamic modelling: a new classification of biomarkers. Pharm Res 2005 Sep; 22 (9): 1432-7
35. De Meyer G, Shapiro F. Biomarker development: the road to clinical utility. Curr Drug Discov 2003; 12: 23-7
36. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003 Jul; 2 (7): 566-80
37. Ilyin SE, Belkowski SM, Plata-Salamán CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol 2004 Aug; 22 (8): 411-6
38. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints in clinical trials: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 Mar; 69: 89-95
39. Gobburu JVS, Jusko WJ. Role of dosage regimen in controlling indirect pharmacodynamic responses. Adv Drug Deliv Rev 2001; 46: 45-57
40. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 2003; 31 (5): 510-8
41. Bellissant E, Sébille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998 Aug; 35 (2): 151-66
42. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992 Apr; 51 (4): 465-73
43. Kumar N, Hendriks BS, Janes KA, et al. Applying computational modeling to drug discovery and development. Drug Discov Today 2006 Sep; 11 (17-18): 806-11
44. Levy G. Relationship between elimination rate of drugs and rate of decline of their pharmacological effect. J Pharm Sci 1964; 53: 342-3
45. Levy G. Kinetics of pharmacological effects. Clin Pharmacol Ther 1966; 7: 362-72
46. Segre G. Kinetics of interaction between drugs and biological systems. Farmaco [Sci] 1968 Oct; 23 (10): 907-18
47. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979 Mar; 25 (3): 358-71
48. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981 Nov-Dec; 6 (6): 429-53
49. Castãneda-Hernández G, Granados-Soto V. Considerations on pharmacodynamics and pharmacokinetics: can everything be explained by the extent of drug binding to its receptor? Can J Physiol Pharmacol 2000; 78: 199-207
50. Levy G. Mechanism-based pharmacodynamic modeling. Clin Pharmacol Ther 1994 Oct; 56 (4): 356-8
51. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993 Aug; 21 (4): 457-78
52. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 1998; 45: 229-39
53. Ramakrishnan R, Dubois DC, Almon RR, et al. Fifth generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methyl-prednisolone in rats. J Pharmacokinet Pharmacodyn 2002; 29: 1-24
54. Gabrielsson J, Jusko WJ, Alari L. Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos 2000; 21: 41-52
55. Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991 Jun; 19 (3): 333-53
56. Yuh L, Beal S, Davidian M, et al. Population pharmacokinetic/ pharmacodynamic methodology and applications: a bibliography. Biometrics 1994 Jun; 50 (2): 566-75
57. Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/ pharmacodynamics modeling: parametric and non-parametric methods. Ther Drug Monit 2000 Jun; 22: 354-65
58. Minto C, Schnider T. Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998 Oct; 46 (4): 321-33
59. Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999 Jul; 37 (1): 41-58
60. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185-209
61. Bonate PL. Recommended reading in population pharmacokinetic pharmacodynamics. AAPS J 2005; 7 (2): E363-73
62. Slikker Jr W, Young JF, Corley RA, et al. Improving predictive modeling in pediatric drug development: pharmacokinetics, pharmacodynamics, and mechanistic modeling. Ann N Y Acad Sci 2005; 1053: 505-18
63. Burton DGA, Allen MC, Bird JLE, et al. Bridging the gap: ageing, pharmacokinetics and pharmacodynamics. J Pharm Pharmacol 2005 Jun; 57: 671-9
64. Grasela Jr TH, Antal EJ, Ereshefsky L, et al. An evaluation of population pharmacokinetics in therapeutic trials: part II. Detection of a drug-drug interaction. Clin Pharmacol Ther 1987 Oct; 42 (4): 433-41
65. Antal EJ, Grasela TH, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials: part III. Prospective data collection versus retrospective data assembly. Clin Pharmacol Ther 1989 Nov; 46 (5): 552-9
66. Guentert TW, Banken L, Hilton S, et al. Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol 1995 Aug; 15 (4 Suppl. 2): 84S-94S
67. Chan PLS, Holford NHG. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001; 41: 625-59
68. Post TM, Freijer JI, de Jongh J, et al. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005; 22: 1038-49
69. Okereke CS. Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson's disease patients experiencing motor fluctuations with levodopa. J Pharm Pharmaceut Sci 2002; 5 (2): 146-61
70. Contin M, Riva R, Albani F, et al. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996 Jun; 30 (6): 463-81
71. Triggs EJ, Charles BG, Contin M, et al. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients. Eur J Clin Pharmacol 1996; 51 (1): 59-67
72. Dietz M, Harder S, Graff J, et al. Levodopa pharmacokinetic- pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease. Clin Pharmacol Ther 2001; 70: 33-41
73. Chan PL, Nutt JG, Holford NH. Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. J Pharmacokinet Pharmacodyn 2004 Jun; 31 (3): 243-68
74. Trocóniz IF, Naukkarinen TH, Ruottinen HM, et al. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther 1998 Jul; 64 (1): 106-16
75. Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209-34
76. Physiological modeling resource [online]. Available from URL: http://www.physiome.org/Models/ [Accessed 2007 Apr 30]
77. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997 Mar; 61 (3): 275-91
78. Chien JY, Friedrich S, Heathman MA, et al. Pharmacokinetics/ pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 2005 Oct; 7 (3): E544-59
79. Mahmood I. Allometric issues in drug development. J Pharm Sci 1999 Nov; 88 (11): 1101-6
80. Poggesi I. Predicting human pharmacokinetics from preclinical data. Curr Opin Drug Discov Devel 2004 Jan; 7 (1): 100-11
81. Buoen C, Bjerrum OJ, Thomsen MS. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol 2005 Oct; 45: 1123-36
82. Emilien G, van Meurs W, Maloteaux JM. The dose-response relationship in phase I clinical trials and beyond: use, meaning, and assessment. Pharmacol Ther 2000; 88: 33-58
83. Aarons L, Karlsson MO, Mentré F, et al. Role of modelling and simulation in phase I drug development. Eur J Pharm Sci 2001; 13: 115-22
84. Evans L, Aarons L, Brearley C. A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from phase I studies. J Pharm Pharmacol 2005; 57 (2): 183-9
85. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil: II. Model application. Anesthesiology 1997 Jan; 86 (1): 24-33
86. Bonate P. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. IDrugs 2001; 4 (9): 1017-20
87. Temple R. Dose response and registration of new drugs. In: Lasagna L, Erill S, Naranjo CA, editors. Dose response relationships in clinical pharmacology. Amsterdam: Excerpta Medica, 1989: 145-70
88. Stanski DR. Model-based drug development: a critical path opportunity [online]. Available from URL: http://www.fda.gov/oc/initiatives/criticalpath/ stanski/stanski.html [Accessed 2007 Apr 26]
89. Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000 Jan-Mar; 25 (1): 49-58
90. Johnson S. The role of simulation in the management of research: what can the pharmaceutical industry learn from the aerospace industry? Drug Inf J 1998; 32: 961-9
91. Holford NHG, Hale M, Ko HC, et al. Simulation in drug development: good practices [online]. Available from URL: http://cdds.ucsf.edu/research/ sddgpreport.php [Accessed 2007 Apr 26]
92. Venitz J. Using exposure-response relationships to define therapeutic index: a proposed approach based on utility functions [online]. Available from URL: www.fda.gov/ohrms/dockets/ac/02/slides/3898S1_06_Venitz.pdf [Accessed 2007 Apr 26]
93. Reigner BG, Williams PE, Patel IH, et al. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development: experience within Hoffmann La Roche. Clin Pharmacokinet 1997 Aug; 33 (2): 142-52
94. Olson SC, Bockbrader H, Boyd RA, et al. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis. Clin Pharmacokinet 2000 May; 38 (5): 449-59
95. Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 2005; 96: 182-92
96. Miller R, Ewy W, Corrigan BW, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005 Apr; 32 (2): 185-97
97. Kuhlmann J, Wensing G. The applications of biomarkers in early clinical drug development to improve decision-making processes. Curr Clin Pharmacol 2006 May; 1 (2): 185-91
98. Lockwood PA, Cook JA, Ewy WE, et al. The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. Pharm Res 2003 Nov; 20 (11): 1752-9
99. Lesko LJ, Rowland M, Peck CC, et al. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 2000 Nov; 17 (11): 1335-44
100. Sanathanan LP, Peck CC. The randomized concentration-controlled trial: an evaluation of its sample size efficiency. Controlled Clin Trials 1991 Dec; 12 (6): 780-94
101. Holford NH. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995 Nov; 29 (5): 287-91
102. Grahnén A, Karlsson MO. Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials? Clin Pharmacokinet 2001; 40 (5): 317-25
103. Johnston A, Holt DW. Concentration-controlled trials: what does the future hold? Clin Pharmacokinet 1995 Feb; 28 (2): 93-9
104. Levy G, Ebling WF, Forrest A. Concentration- or effect-controlled clinical trials with sparse data. Clin Pharmacol Ther 1994 Jul; 56 (1): 1-8
105. Ebling WF, Levy G. Population pharmacodynamics: strategies for concentration- and effect-controlled clinical trials. Ann Pharmacother 1996; 30: 12-9
106. Fullerton T, Forrest A, Levy G. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study: an investigation by simulations. J Pharm Sci 1996 Jun; 85 (6): 600-7
107. Smith DA. Pharmacokinetics and pharmacodynamics in toxicology. Xenobiotica 1997; 27 (5): 513-25
108. Festing MF. Genetic variation in outbred rats and mice and its implications for toxicological screening. J Exp Anim Sci 1993 Sep; 35 (5-6): 210-20
109. Misenheimer TM, Suttie JW. Warfarin resistance in the Chicago strain of rats. Biochem Pharmacol 1990; 40: 2079-84
110. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005 Oct; 7 (3): E503-12
111. Smith DA. Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment. Eur J Drug Metab Pharmacokinet 1993 Jan-Mar; 18 (1): 31-9
112. Lavé T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 1999 Mar; 36 (3): 211-31
113. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 2002 Jan; 5: 116-26
114. Rohatagi S, Appajosyula S, Derendorf H. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44: 37-47
115. Tayab ZR, Hochhaus G. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opin Drug Deliv 2005; 2 (3): 519-32
116. Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 2004 Dec; 58 (6): 601-8
117. Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 2002 Jun; 3 (3): 289-309
118. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003 Jul; 4 (4): 397-410
119. US FDA. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Preliminary concept paper, draft 4 (June 10, 2004) [online]. Available from URL: http://www.fda.gov/cder/ guidance/6378dft.htm [Accessed 2007 Apr 26]
120. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs. Current step 4 version dated 12 May 2005 [online]. Available from URL: http://www.ich.org/LOB/media/ MEDIA1476.pdf [Accessed 2007 Apr 26]
121. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J 2005 Oct; 7 (3): E609-24
122. Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet 1997 May; 32 (5): 345-56
123. Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent research. Clin Pharmacokinet 1994 Sep; 27 (3): 202-15
124. Boissel JP, Nony P. Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet 2002; 41 (1): 1-6
125. Vrijens B, Goetghebeur E. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies. Stat Med 2004; 23: 531-44
126. International Conference on Harmonisation (ICH). E8 guideline on general considerations for clinical trials. Fed Reg 1997 Dec; 62 (242): 66113-9
127. US FDA. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products [online]. Available from URL: http://www.fda.gov/cder/guidance/1397fnl.pdf [Accessed 2007 Apr 26]
128. Peck CC, Rubin DB, Sheiner LB. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Ther 2003 Jun; 73 (6): 481-90
129. Mandema J, Stanski D. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619-35
130. Lee H, Yim DS, Zhou H, et al. Evidence of effectiveness: how much can we extrapolate from existing studies? AAPS J 2005; 7 (2): E467-74
131. Lieberman R, McMichael J. Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development. Ther Drug Monit 1996; 18: 423-8
132. Machado SG, Miller R, Hu C. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. Stat Methods Med Res 1999 Sep; 8: 217-45
133. Lesko LJ, Atkinson Jr AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001; 41: 347-66
134. Gobburu JVS, Marroum PJ. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin Pharmacokinet 2001; 40 (12): 883-92
135. Gobburu JVS, Lipicky RJ. Dose-response relationship characterization in current drug development: do we have a problem? [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3656b2a.pdf [Accessed 2007 Apr 26]
136. US FDA. Guidance for industry: exposure-response relationships. Study design, data analysis, and regulatory applications [online]. Available from URL: http://www.fda.gov/cder/guidance/5341fnl.pdf [Accessed 2007 Apr 26]
137. Lesko L. Proposal for end-of-phase 2A (EOP2A) meeting, FDA Advisory Committee for Pharmaceutical Sciences. Clinical Pharmacology Subcommittee [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/slides/ 3998s1.htm [Accessed 2007 Apr 26]
138. Cross J, Lee H, Westelinck A, et al. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Safety 2002 Sep; 11 (6): 439-46
139. Stark JG, Werner S, Homrighausen S, et al. Pharmacokinetic/ pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. J Pharmacokinet Pharmacodyn 2006 Aug; 33 (4): 441-59
140. Äbelö A, Andersson M, Holmberg AA, et al. Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog. Eur J Pharm Sci 2006 Oct; 29 (2): 91-101
141. Mathôt RAA, Geus WP. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. Clin Pharmacol Ther 1999; 66: 140-51
142. Cremers SCLM, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005; 44 (6): 551-70
143. Pillai G, Gieschke R, Goggin T, et al. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004 Dec; 58 (6): 618-31
144. Brown SA, Nelson RW, Bottoms GD. Models for the pharmacokinetics and pharmacodynamics of insulin in alloxan-induced diabetic dogs. J Pharm Sci 1987 Apr; 76 (4): 295-9
145. Rydberg T, Jönsson A, Karlsson MO, et al. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 1997 Apr; 43 (4): 373-81
146. Van Griensven JM, Jusko WJ, Lemkes HH, et al. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin Pharmacol Ther 1995 Dec; 58 (6): 631-40
147. Lin S, Chien YW. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models. J Pharm Pharmacol 2002; 54: 791-800
148. Osterberg O, Erichsen L, Ingwersen SH, et al. Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodyn 2003; 30: 221-35
149. Mager DE, Abernethy DR, Egan JM, et al. Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 2004; 311 (2): 830-5
150. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43 (12): 781-801
151. Haidar SH, Johnson SB, Fossler MJ, et al. Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks. Pharm Res 2002; 19 (1): 87-91
152. Raje S, Cornish J, Newman AH, et al. Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling. Pharm Res 2005 Apr; 22 (4): 603-12
153. Valle M, Barbanoj MJ, Jané F. Pharmaco-electroencephalography and pharmacokinetic-pharmacodynamic modeling in basic research: focus on human pharmacology. Methods Find Exp Clin Pharmacol 2002; 24 Suppl. D: 129-37
154. Barbanoj MJ, Valle M, Kulisevsky J, et al. Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario. Methods Find Exp Clin Pharmacol 2002; 24 Suppl. D: 139-44
155. Tuk B, Van Oostenbruggen MF, Herben VMM, et al. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and α-OH-midazolam. J Pharmacol Exp Ther 1999; 289: 1067-74
156. Lemmens HJM, Dyek JB, Shafer SL, et al. Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther 1994; 56: 261-71
157. Dingemanse J, van Gerven JM, Schoemaker RC, et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects, Br J Clin Pharmacol 1997 Nov; 44 (5): 477-86
158. Rehberg B, Bouillon T, Zinserling J, et al. Comparative pharmacodynamic modeling of the electroencephalography-slowing effect of isoflurane, sevoflurane, and desflurane. Anesthesiology 1999; 91: 397-405
159. Hering WJ, Ihmsen H, Langer H, et al. Pharmacokinetic-pharmacodynamic modeling of the new steroid hypnotic eltanolone in healthy subjects. Anesthesiology 1996 Dec; 85 (6): 1290-9
160. Karlsson MO, Schoemaker RC, Kemp B. A pharmacodynamic Markov mixed-effect model for the effect of temazepam on sleep. Clin Pharmacol Ther 2000; 68: 175-88
161. Tuk B, Oberyé JJL, Pieters MSM, et al. Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. Clin Pharmacol Ther 1997; 62: 444-52
162. Jönsson S, Cheng Y-F, Edenius C, et al. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke. Clin Pharmacokinet 2005; 44 (8): 863-78
163. Kimko HC, Reele SSB, Holford NHG, et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 65: 568-77
164. Matsui-Sakata A, Ohtani H, Sawada Y. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab Pharmacokinet 2005; 20 (3): 187-99
165. Dewey SL, Smith GS, Logan J, et al. Serotoninergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995; 15: 821-9
166. Toutain PL, Del Castillo JRE, Bousquet-Mélou A. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res Vet Sci 2002; 73: 105-14
167. Maglio D, Nicolau DP. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimen. Methods Find Exp Clin Pharmacol 2004; 26 (10): 781-8
168. Mouton JH, Schmitt-Hoffmann A, Shapiro S, et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 2004; 48: 1713-8
169. Bhavnani SM, Hammel JP, Cirincione BB, et al. Use of pharmacokinetic- pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005 Sep; 49 (9): 3944-7
170. European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products (CPMP/EWP/2655/99) [online]. Available from URL: http://www.emea.eu.int/pdfs/ human/ewp/265599en.pdf [Accessed 2007 Apr 26]
171. Müller M, dela Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissues. Antimicrob Agents Chemother 2004; 48: 1441-53
172. Nightingale CH. Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibodies. Pharmacotherapy 2005; 25: 146S-9S
173. Brunner M, Derendorf H, Müller M. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr Opin Pharmacol 2005; 5: 495-9
174. Liu P, Rand KH, Obermann B, et al. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 2005; 25: 120-9
175. Rosario MC, Jacqmin P, Dorr P, et al. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc. Clin Pharmacol Ther 2005; 78: 508-19
176. Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004; 93: 2184-204
177. Kamiya H, Akita H, Harashima H. Pharmacokinetic and pharmacodynamic
178. Yu RZ, Geary RS, Levin AA. Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assessments of antisense oligonucleotides. Curr Opin Drug Discov Devel 2004; 7 (2): 195-203
179. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2006 Apr; 44: 331-47
180. DeLamarter J, Fumero S. Today's alliances for tomorrow's medicines. Drug Discov World 2002; 3 Fall: 9-14
181. Duconge J, Castillo R, Crombet T, et al. Integrated pharmacokinetic- pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci 2004; 21: 261-70
182. Khor SP, McCarthy K, Dupont M, et al. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. J Pharmacol Exp Ther 2000; 293 (2): 618-24
183. Marshall S, Macintyre F, James I, et al. Role of mechanisticallybased pharmacokinetic/pharmacodynamic models in drug development: a case study of a therapeutic protein. Clin Pharmacokinet 2006; 45 (2): 177-97
184. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163-9
185. Blesch KS, Gieschke R, Tsukamoto Y, et al. Clinical pharmacokinetic/ pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs 2003; 21: 195-23
186. Friberg LEA, Henningsson H, Maas L, et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20: 4713-21
187. Karlsson MO, Anchall T, Lena E, et al. Pharmacokinetic/pharmacodynamic modeling in oncological drug development. Pharmacol Toxicol 2005; 96: 206-11
188. Latz JE, Karlsson MO, Rusthoven JJ, et al. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006; 57: 412-26
189. Latz JE, Rusthoven JJ, Karlsson MO, et al. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006; 57: 427-35